Gilead Punished By HCV Patent Infringement Loss

Shock Exchange profile picture
Shock Exchange


  • A judge ordered Gilead to pay $2.54 billion in damages for infringing upon Merck's HCV patents.
  • Gilead already has 99 problems. Its HCV sales are in free fall, and the company has not made the blockbuster deal bulls have asked for.
  • A sizeable payout could cut into the company's one competitive advantage: its $32 billion war chest.
  • Gilead is a sell.

Gilead (NASDAQ:GILD) has taken on all comers in the HCV market. It has previously fought off patent infringement claims from Merck (MRK) and AbbVie (ABBV). I thought the noise over who owned the patent for Sovaldi and Harvoni was over. However, a federal jury recently ordered the company to pay $2.54 billion in damages for infringing upon Merck's HCV patents:

Gilead Sciences Inc. was told by a federal jury to pay $2.54 billion to Merck & Co. for using a patented invention as the basis for its blockbuster drugs for the potentially deadly liver disease hepatitis C - the biggest patent-infringement verdict in U.S. history... The infringement also was found to be willful, meaning the judge could increase the damage award by as much as three times the amount set by the jury. The jury said on Thursday that Gilead owed 10 percent royalties on $25.4 billion in total sales for the two drugs.

Gilead has vowed to appeal the ruling. The stock was down over 1% midday on Friday.

Is Merck Throwing Stuff Up On The Wall?

At issue is a 2009 patent for a compound created by Merck's Idenix unit. Merck claims the compound is the basis for HCV treatments used by Gilead's Sovaldi/Harvoni. Merck acquired Idenix in 2014. Sovaldi was approved by the FDA in 2013, and Harvoni was approved one year later. They are both considered two of the most successful drug launches in history. They also sliced into Merck's HCV sales. In 2012, Merck's Victrelis and PegIntron generated combined sales of $1.2 billion in the HCV space. They fell to an estimated $200 million shortly after Gilead's HCV drugs hit the market.

One thing Merck is certain of is that Gilead infringed on its patents. The question remains: "Which patents?" Merck previously claimed Pharmasset used its patents published

This article was written by

Shock Exchange profile picture
The Shock Exchange has a B.A. in economics and MBA from a top 10 business school. He has over 10 years of M&A / corporate finance experience. Currently head the New York Shock Exchange, financial literacy program based in Brooklyn, NY.His book, "Shock Exchange: How Inner-City Kids From Brooklyn Predicted the Great Recession and the Pain Ahead", predicted pain ahead for the U.S. economy and financial markets.In 2014 the law firm of Kirby, McInerney, LLP brought a class action lawsuit against Molycorp, Inc. for "materially misleading statements" in its financial statements. Kirby, McInerney used investigative journalism from the Shock Exchange to buttress its case. That's the discipline the Shock Exchange brings to every situation he covers for SA.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (98)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.